Prosecution Insights
Last updated: November 04, 2026
Application No. 18/275,603

Compound For Treating or Preventing Vimentin-Mediated Diseases

Non-Final OA §102§112§DOUBLEPATENT
Filed
Aug 12, 2024
Priority
Feb 03, 2021 — CN 202110148083.9 +2 more
Examiner
SEITZ, ANTHONY JOSEPH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aluda Pharmaceuticals Inc.
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
148 granted / 217 resolved
+8.2% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
279
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
27.6%
-12.4% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 217 resolved cases

Office Action

§102 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election of Species and Status of the Claims Applicant’s election without traverse of ‘compound L2’ as the single specific compound and ‘acute respiratory distress syndrome’ as the single specific disease in the response filed on August 11th 2026 is acknowledged. Claims 1-20 are pending. Claims 6-7, and 17-20 are withdrawn from further consideration as being directed towards nonelected species until a generic claim has been found allowable. Claims 1-5, and 8-16 are examined on their merits. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The Information Disclosure Statements filed on August 11th 2026 and January 17th 2025 are in compliance with the provisions of 37 CFR 1.97 and have been considered in full. A signed copy of references cited from the IDS is included with this Office Action. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-5, and 8-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claims contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In order to determine compliance with the enablement requirement of 35 U.S.C. 112(a), the Federal Circuit developed a framework of factors in In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), referred to as the Wands factors to assess whether any necessary experimentation required by the specification is "reasonable" or is "undue." Consistent with Amgen Inc. et al. v. Sanofi et al., 598 U.S. 594, 2023 USPQ2d 602 (2023), the Wands factors continue to provide a framework for assessing enablement in a utility application or patent, regardless of technology area. See Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. Sanofi et al., 89 FR 1563 (January 10, 2024). These factors include, but are not limited to: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. The Breadth of the Claims and the Nature of the Invention The claims are directed towards the treatment or prevention of two categories of diseases via administration of compounds of the genus, PNG media_image1.png 107 285 media_image1.png Greyscale . Such compounds have been demonstrated in the art to act as binders of the cytoskeletal protein, vimentin, which is involved in maintaining mechanical stability of the cell, as well as various cellular processes including cellular transport1. Applicant’s method of treatment is separated into two the treatment/prevention of two separate disease categories: Diseases involving cell endocytosis, exocytosis, and endosomal trafficking Diseases involving an inadequate quantity and/or function of regulatory T cells The breadth of the claims is thus defined by the scope in which these two disease categories encompass. The first category is defined as “diseases involving endocytosis, exocytosis, and endosomal trafficking.” That is, diseases wherein membrane-vesicle trafficking is involved in the disease process. As endosomal trafficking plays a factor in a large variety of cellular processes, such diseases are numerous in nature. For example, the mismanagement of cellular recycling processes is a major factor in pathological protein aggregation, and thus endosomal trafficking would be implicated in a variety of neurodegenerative disorders, including Alzheimer’s disease, Lewy body disorders, and Huntington’s disease. Similarly, disruptions in the endocytic transport route of plasma membrane-to-endosome in neurons may impair the uptake of brain-derived neurotrophic factor. As BDNF plays a significant regulatory role in neuroinflammatory responses, this can lead to chronic neuroinflammation and neuronal loss, such as that found in Parkinson’s disease and amyotrophic lateral sclerosis2. PNG media_image2.png 730 759 media_image2.png Greyscale 2. The disorders linked to endosomal trafficking are not limited in nature to neurological disorders. The endosomal recycling pathways are well-known to be hijacked by bacteria and viruses as a means of entering the cell and supporting their replication. One well-known example is the Hepatitis C virus, which enters the cell via receptor-mediated endocytosis followed by a fusion step within an endosomal compartment3. This is just one of many infectious pathogens that uses a similar pathway, as endosomal trafficking is implicated in the pathways of pathogens as varied as Chlamydia trachomatis, Legionella pneumophila, Salmonella Typhimurium, HIV, SARS-CoV-2, and Human papillomavirus4. Furthermore, the extent to which the endosome is implicated in different conditions goes beyond the endosomal trafficking itself, as the conditions within the endosome are found to be pathologically linked to the development of various cancers. See Ko5: “High cytoplasmic pH is permissive to mitotic and meiotic re-entry in cells, and bypasses cell cycle checkpoints to promote cancer cell proliferation. Elevated cytoplasmic pH also helps cancer cells evade apoptosis since programmed cell death requires low cytoplasmic pH [6, 7]. In addition, the alkaline intracellular environment fosters genomic instability, which drives cancer evolution and therapeutic resistance by the generation of new subclones that establish the hierarchical organization of a tumor. Elevated H+ extrusion has been proposed as a driver of the metabolic shift toward aerobic glycolysis, well known as the Warburg effect [8]. Furthermore, the acidic extracellular microenvironment in cancer promotes the expression of stem cell markers, angiogenic factors and hypoxia response factors enhancing tumor aggressiveness and angiogenic potential [9–11]. In malignant cells, a change in activity or localization of plasma membrane transporters favors tumor cell migration and metastasis.” Thus, the category of “diseases involving cell endocytosis, exocytosis, and endosomal trafficking,” is found to be very broad, encompassing numerous pathogenic infections, cancers, neurological disorders, inflammatory disorders, and more. The conditions in which dysfunction in regulatory T cells are implicated are equally numerous. Such cells are responsible for maintaining immunologic self-tolerance. That is, regulatory T cells (Tregs) help the body recognize itself and prevent immune responses on the body’s own cells. Thus, dysfunction in such Tregs is responsible for many inflammatory and autoimmune diseases. Examples of such conditions are inflammatory bowel disease (IBD), in which the body exhibits abberant inflammation towards the normal bacterial flora in the gut6, and Type 1 diabetes, in which the immune system mistakenly attacks the beta cells in the pancreas in which insulin is produced: PNG media_image3.png 654 585 media_image3.png Greyscale “In the healthy beta cell, there is an autophagosome, which is a sac-like structure that engulfs unnecessary or damaged cellular components. The autophagosome then fuses with a lysosome, which is a cellular waste disposal unit, and the engulfed components are degraded. In the stressed beta cell, the autophagosome formation is compromised, leading to a buildup of nonfunctional lysosomes and defective degradation of cellular components. This can lead to endoplasmic reticulum (ER) stress, which is a condition in which the ER, a cellular organelle responsible for protein folding, becomes overloaded. ER stress can lead to the release of neo antigens or peptides, which are molecules that can trigger an immune response. In the context of the figure, this immune response can be harmful to the beta cells, leading to their destruction.”7 The category of “diseases involving an inadequate quantity and/or function of regulatory T cells” also shares significant overlap with the category of “diseases involving cell endocytosis, exocytosis, and endosomal trafficking,” including inflammatory diseases such as multiple sclerosis, cancerous tumors, and many infections, including both hepatitis C and HIV6. Thus, the breadth of the claims is very large, encompassing the treatment of pathogenic infections, autoimmune diseases, inflammatory diseases, cancers, neurological disorders, and more. The State of the Prior Art, The Level of Predictability in the Art The claims are directed towards the treatment of a wide variety of diseases via administration of a genus of vimentin-binding compounds. Vimentin binding compounds have previously been demonstrated in the art to inhibit exosome secretion, but their therapeutic effects are far from clear. For example, see Wu, who describes the administration of the vimentin-binding compound R491 to cancer cells: “The compound R491 induced a rapid and reversible intracellular vacuolization in various types of cancer cells. This phenotype did not result in an inhibition of cancer cell growth, which was consistent with our finding from a protein array that R491 did not reduce levels of major oncoproteins in cancer cells. Morphological and quantitative analyses on the intracellular vacuoles and extracellular exosomes revealed that in response to R491 treatment, the exosomes released from the cells were significantly reduced, while the exosomes retained as intra-luminal vesicles inside the cells were subsequently degraded. Vim+/− cells had lower amounts of vimentin and accordingly, lower amounts of both the retained and the released exosomes than Vim+/+ cells had, while the vimentin-binding compound R491 inhibited only the release of exosomes.”8 In contrast, see Trogden, who describes the administration of simvastatin to adrenal carcinoma cells. Similar to R491, simvastatin binds to vimentin in the cancer cells. However, unlike the R491, the simvastatin causes cytotoxic effects within the cancer cells, resulting in cell death9: PNG media_image4.png 410 1009 media_image4.png Greyscale . Thus, while the mechanism of action of these drugs appears to be well-understood, the therapeutic effects are far less predictable. While vimentin binding/inhibition is being explored as a therapeutic mechanism for many different cancers, one of ordinary skill in the art would not find the anti-cancer activity of compounds with this activity to be predictable10. Furthermore, it is well-known in the art that different cancers follow different clinical courses, necessitating different therapies, and that the boundaries between different classes of cancer are not always clear, which introduces a need for constant re-evaluation of therapies as more information is learned over the course of a treatment regimen11. Regarding the other implicated diseases, while vimentin has been demonstrated to play a contributing role in the development of neurodegenerative disorders, such as Alzheimer’s disease and Huntington’s disease1213, outside of Withaferin A (a natural steroidal lactone from Withania somnifera that is known to act via many different pathways)14, it does not appear that any vimentin binding agents have been demonstrated, nor even tested for efficacy in the treatment of such disorders. While vimentin-related pathways are often described in studies relating to pathogen entry15, studies relating to the actual treatment of infectious diseases appear to be almost exclusively related to the treatment of COVID-19161718. That is to say, the nature of the art of treating all of the aforementioned diseases is found to be highly unpredictable, and no one treatment option would be expected to be effective in treating all of the diseases described. The Level of One of Ordinary Skill in the Art The method of the invention relates to the treatment of various diseases, including but not limited to pathogenic infections, autoimmune diseases, inflammatory diseases, cancers, and neurological disorders. One of ordinary skill in the art of medicine alone would be at least a doctor, who has completed medical school. Several of the subgenera of diseases described involve several years of specialization beyond medical school for one to be considered “one of ordinary skill in the art.” For example, an expert in any of cancers, autoimmune diseases, and neurological disorders, would be an “oncologist,” “rheumatologist,” and “neurologist,” respectively. The Amount of Direction Provided by the Inventor, The Existence of Working Examples, and The Quantity of Experimentation Needed to Make or Use the Invention Based on the Disclosure Regarding the working examples and direction provided by the inventor, the data provided by the inventor demonstrates that the compounds used in the instant method alter vimentin organization and mobility, thereby inhibiting endocytosis/endosomal trafficking and exosome release. Applicant provides experimental evidence demonstrating efficacy both in the treatment of SARS-CoV2 infection, as well as in the inhibition of the infection of cells by the virus. Applicant further demonstrates that the compounds activate and promote regeneration of regulatory T cells in vivo, yielding positive therapeutic results in an induced colitis model, as well as in a multiple sclerosis model. Regarding applicant’s anticancer studies, the results are more complicated. Applicant tests the compounds in lung cancer, pancreatic cancer, glioma, and liver cancer models, and demonstrates that the compounds DO NOT show efficacy in the treatment of tumors, and in fact may be contraindicated for such a purpose. However, the compounds appear to have a dose-dependent inhibitory effect on the cancer cell migration/invasion, suggesting utility in a metastatic setting. In summary, it can be said that applicant’s working examples are largely mechanistic in nature, suggesting efficacy in the treatment of various categories of diseases, but requiring an undue amount of experimentation in order to expand beyond the scope of the few conditions described. As evidenced by applicant’s cancer studies, the results are suggestive of therapeutic efficacy, but are not clearly enabling for the full scope of the diseases recited in the claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5, and 8-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Luoda Biosciences (WO 2017193954A1 published on November 16th 2017; Google Patents Translation Attached). The claims are directed towards a method of treating or preventing diseases involving inadequate function of regulatory T cells via administration of applicant’s elected species of: PNG media_image5.png 306 500 media_image5.png Greyscale . Diseases involving such T cell dysregulation are numerous in nature, but one in particular is the Hepatitis C virus, which is well-known to involve the dysregulation of T cell function19. Thus, hepatitis C would be considered one of said diseases “involving inadequate function of regulatory T cells.” Claim 1 is directed towards a method of treating or preventing diseases involving inadequate function of regulatory T cells via administration of a compound of formula A: PNG media_image1.png 107 285 media_image1.png Greyscale . Luoda Biosciences teaches applicant’s elected species, PNG media_image5.png 306 500 media_image5.png Greyscale (Louda Biosciences, Translation, pg. 11), as well as administration of the compound to treat Hepatitis C infections (Louda Biosciences, Translation, pg. 16-17). Louda Biosciences therefore anticipates claim 1. Claims 2-5, 8, and 11-16 only limit the compound genus of claim 1 to precisely that which includes applicant’s elected species above. Claims 2-5, 8 and 11-16 are thereby anticipated by Louda Biosciences for the same reasons as claim 1. Claim 9 limits the ‘disease related to the inadequate function of regulatory T cells,’ of claim 1 to an inflammatory disease. As Hepatitis C is well-known to involve the inflammation of the liver20, Louda Biosciences anticipates claim 9 for the same reasons as claim 1. Claim 10 limits claim 9 by requiring the disease associated with inadequate regulatory T cell function to be selected from a group that includes “diseases featuring an inflammatory component.” As Hepatitis C qualifies as such a disease (see above), Louda Biosciences anticipates claim 10 for the same reasons as claim 9. Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5, and 8-16 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 10,611,736 in view of Zhang and Zhang (Zhang M, Zhang S. T Cells in Fibrosis and Fibrotic Diseases. Front Immunol. 2020 Jun 26;11:1142). Claims 1-5, 8, and 11-16 are directed towards a method of treating or preventing diseases involving inadequate function of regulatory T cells via administration of applicant’s elected species of: PNG media_image5.png 306 500 media_image5.png Greyscale . The reference patent teaches an identical compound (reference patent, claim 8), as well as the treatment of tissue fibrosis with the compound (reference patent, claim 16). As tissue fibrosis is known as a disease involving regulatory T cell dysregulation21, tissue fibrosis qualifies as a “disease involving inadequate function of regulatory T cells.” Claims 9 and 10 limit the disease of claim 1 to one featuring an inflammatory component, of which tissue fibrosis is well known to include, as dysregulated inflammation is a major contributor to excessive scar tissue formation (Zhang and Zhang, pg. 2). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anthony Seitz whose telephone number is (703)756-4657. The examiner can normally be reached 7:30 AM ET - 5:00 PM ET M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANTHONY JOSEPH SEITZ/Examiner, Art Unit 1629 1 See Yuan (Yuan Z, Janmey PA, McCulloch CA. Structure and function of vimentin in the generation and secretion of extracellular vimentin in response to inflammation. Cell Commun Signal. 2025 Apr 18;23(1):187) 2 See Dong (Dong, J., Tong, W., Liu, M. et al. Endosomal traffic disorders: a driving force behind neurodegenerative diseases. Transl Neurodegener 13, 66 (2024)) 3 Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006 Jul;80(14):6964-72 4 Yong X, Mao L, Shen X, Zhang Z, Billadeau DD, Jia D. Targeting Endosomal Recycling Pathways by Bacterial and Viral Pathogens. Front Cell Dev Biol. 2021 Mar 4 5 Ko M, Quiñones-Hinojosa A, Rao R. Emerging links between endosomal pH and cancer. Cancer Metastasis Rev. 2020 Jun;39(2):519-534 6 Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR, Vignali DA. The development and function of regulatory T cells. Cell Mol Life Sci. 2009 Aug;66(16):2603-22 7 See Saptarshi (Saptarshi Roy, Pravil Pokharel, Jon D. Piganelli, Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes, Molecular Metabolism, Volume 88, 2024) 8 Wu J, Xie Q, Liu Y, Gao Y, Qu Z, Mo L, Xu Y, Chen R and Shi L (2021) A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility. Front. Pharmacol. 12:627394 9 Trogden KP, Battaglia RA, Kabiraj P, Madden VJ, Herrmann H, Snider NT. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. FASEB J. 2018 May;32(5):2841-2854 10 Strouhalova K, Prechová M, Gandalovicová A, Brábek J, Gregor M, Rosel D. Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers (Basel). 2020 Jan 11;12(1) 11 Golub et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999 Oct 15;286(5439):531-7 12Zhang L, Wang J, Yan Y, Xiang L, Zhai X, Cai L, Sun Z, Pi M, Xiong Q, Zhou H, Gui Y, Wang X, Shu X, Xia Y. Vimentin Fragmentation and Its Role in Amyloid-Beta Plaque Deposition in Alzheimer's Disease. Int J Mol Sci. 2025 Mar 21;26(7):2857 13 Bauer PO, Hudec R, Goswami A, Kurosawa M, Matsumoto G, Mikoshiba K, Nukina N. ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. Mol Neurodegener. 2012 Aug 28;7:43 14 Yang L, Zou Y, Fan J, Yin P, Qin H, Li Z, Wu F, Li X, Teng H, Zhang Y, Chen X, Li SC. Withaferin A Rescues Brain Network Dysfunction and Cognitive Deficits in a Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2025 May 29;18(6):816 15 Arrindell J and Desnues B (2023) Vimentin: from a cytoskeletal protein to a critical modulator of immune response and a target for infection. Front. Immunol. 14:1224352. 16 Prasenohadi P, Burhan E, Dhunny S, Suharno W, Wabnitz P, Kim YW, Petrosillo N. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961 17 Suprewicz Ł, Swoger M, Gupta S, Piktel E, Byfield FJ, Iwamoto DV, Germann D, Reszeć J, Marcińczyk N, Carroll RJ, Janmey PA, Schwarz JM, Bucki R, Patteson AE. Extracellular Vimentin as a Target Against SARS-CoV-2 Host Cell Invasion. Small. 2022 18 Li Z, Wu J, Zhou J, Yuan B, Chen J, Wu W, Mo L, Qu Z, Zhou F, Dong Y, Huang K, Liu Z, Wang T, Symmes D, Gu J, Sho E, Zhang J, Chen R, Xu Y. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. mBio. 2021 Oct 26;12(5):e0254221 19 For evidentiary support, see Tseng (Tseng, KC., Ho, YC., Hsieh, YH. et al. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C . J Gastroenterol 47, 823–833 (2012)) 20 For evidentiary support, see Li (Li et al., Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018 Dec 21;24(47):5297-5311) 21 For evidentiary support, see Zhang and Zhang (Zhang M, Zhang S. T Cells in Fibrosis and Fibrotic Diseases. Front Immunol. 2020 Jun 26;11:1142)
Read full office action

Prosecution Timeline

Aug 12, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §102, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758536
COMBINATION OF A SK2 INHIBITOR AND AN INHIBITOR OF A CHECKPOINT PATHWAY, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
5y 3m to grant Granted Oct 13, 2026
Patent 12759985
COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES
2y 10m to grant Granted Oct 13, 2026
Patent 12760035
COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12760020
SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF
2y 8m to grant Granted Oct 13, 2026
Patent 12751938
THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
95%
With Interview (+26.9%)
3y 5m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 217 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month